Pharmaceutical company Aptalis Holdings files for a $500 million IPO


Shutterstock photo

Aptalis Holdings, which develops and markets therapies for cystic fibrosis and gastrointestinal disorders, filed on Thursday with the SEC to raise up to $500 million in an initial public offering. The Bridgewater, NJ-based company, which was founded in 1982 and booked $688 million in revenue for the fiscal year ended September 30, 2013, plans to list on the NASDAQ under the symbol APTA. Aptalis Holdings initially filed confidentially on November 4, 2013. Goldman Sachs and J.P. Morgan are the joint bookrunners on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by